While pharmacological inhibition of Akt kinase has been regarded as a promising anti-cancer strategy, most of the Akt inhibitors that have been developed are enzymatic inhibitors that target the kinase active site of Akt. Another key cellular regulatory event for Akt activation is the translocation of Akt kinase to the cell membrane from the cytoplasm, which is accomplished through the pleckstrin homology (PH) domain of Akt. However, compounds specifically interacting with the PH domain of Akt to inhibit Akt activation are currently limited. Here we identified a compound, lancemaside A (LAN-A), which specifically binds to the PH domain of Akt kinase. First, our mass spectra analysis of cellular Akt kinase isolated from cells treated with LAN-A revealed that LAN-A specifically binds to the PH domain of cellular Akt kinase. Second, we observed that LAN-A inhibits the translocation of Akt kinase to the membrane and thus Akt activation, as examined by the phosphorylation of various downstream targets of Akt such as GSK3β, mTOR and BAD. Third, in a co-cultured cell model containing human lung epithelial cancer cells (A549) and normal human primary lung fibroblasts, LAN-A specifically restricts the growth of the A549 cells. LAN-A also displayed anti-proliferative effects on various human cancer cell lines. Finally, in the A549-luciferase mouse transplant model, LAN-A effectively inhibited A549 cell growth with little evident cytotoxicity. Indeed, the therapeutic index of LAN-A in this mouse model was >250, supporting that LAN-A is a potential lead compound for PH domain targeting as a safe anti-cancer Akt inhibitor.
References
[1]
Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489–501.
[2]
Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13: 2905–2927.
[3]
Muller EJ, Williamson L, Kolly C, Suter MM (2008) Outside-in signaling through integrins and cadherins: a central mechanism to control epidermal growth and differentiation? J Invest Dermatol 128: 501–516.
[4]
Sasaki AT, Firtel RA (2006) Regulation of chemotaxis by the orchestrated activation of Ras, PI3K, and TOR. Eur J Cell Biol 85: 873–895.
[5]
Krycer JR, Sharpe LJ, Luu W, Brown AJ (2010) The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab 21: 268–276.
[6]
Jiang BH, Liu LZ (2008) AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets 8: 19–26.
[7]
Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497–5510.
[8]
Knowles MA, Platt FM, Ross RL, Hurst CD (2009) Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 28: 305–316.
[9]
Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, et al. (2011) Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review). Int J Oncol
[10]
Dienstmann R, Rodon J, Markman B, Tabernero J (2011) Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2. Recent Pat Anticancer Drug Discov 6: 210–236.
[11]
Falasca M (2010) PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des 16: 1410–1416.
[12]
Benbrook DM, Masamha CP (2011) The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis. Curr Cancer Drug Targets 11: 586–599.
[13]
Harris TK (2003) PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design. IUBMB Life 55: 117–126.
[14]
Redaelli C, Granucci F, De Gioia L, Cipolla L (2006) Synthesis and biological activity of Akt/PI3K inhibitors. Mini Rev Med Chem 6: 1127–1136.
[15]
Lindsley CW, Barnett SF, Layton ME, Bilodeau MT (2008) The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets 8: 7–18.
[16]
Okuzumi T, Ducker GS, Zhang C, Aizenstein B, Hoffman R, et al. (2010) Synthesis and evaluation of indazole based analog sensitive Akt inhibitors. Mol Biosyst 6: 1389–1402.
[17]
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101.
[18]
Kawakami Y, Nishimoto H, Kitaura J, Maeda-Yamamoto M, Kato RM, et al. (2004) Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem 279: 47720–47725.
[19]
Lynch DK, Ellis CA, Edwards PA, Hiles ID (1999) Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene 18: 8024–8032.
[20]
Toker A, Newton AC (2000) Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 275: 8271–8274.
[21]
Rebecchi MJ, Scarlata S (1998) Pleckstrin homology domains: a common fold with diverse functions. Annu Rev Biophys Biomol Struct 27: 503–528.
[22]
Lemmon MA (2007) Pleckstrin homology (PH) domains and phosphoinositides. Biochem Soc Symp 81–93.
[23]
Cheng JQ, Altomare DA, Klein MA, Lee WC, Kruh GD, et al. (1997) Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 14: 2793–2801.
[24]
Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR (1998) Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 21: 81–86.
[25]
Kim D, Sun M, He L, Zhou QH, Chen J, et al. (2010) A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J Biol Chem 285: 8383–8394.
[26]
Kim Y, Hollenbaugh JA, Kim DH, Kim B (2011) Novel PI3K/Akt Inhibitors Screened by the Cytoprotective Function of Human Immunodeficiency Virus Type 1 Tat. PLoS One 6: e21781.
[27]
Noh KH, Kang TH, Kim JH, Pai SI, Lin KY, et al. (2009) Activation of Akt as a mechanism for tumor immune evasion. Mol Ther 17: 439–447.
[28]
Liu Y, Wang Y, Yamakuchi M, Masuda S, Tokioka T, et al. (2001) Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I tax. Oncogene 20: 2514–2526.
[29]
Street A, Macdonald A, Crowder K, Harris M (2004) The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 279: 12232–12241.
[30]
Chugh P, Bradel-Tretheway B, Monteiro-Filho CM, Planelles V, Maggirwar SB, et al. (2008) Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology 5: 11.
[31]
Chugh P, Fan S, Planelles V, Maggirwar SB, Dewhurst S, et al. (2007) Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in a human microglial cell line. J Mol Biol 366: 67–81.
[32]
Joh EH, Kim DH (2010) A sensitive liquid chromatography-electrospray tandem mass spectrometric method for lancemaside A and its metabolites in plasma and a pharmacokinetic study in mice. J Chromatogr B Analyt Technol Biomed Life Sci 878: 1875–1880.
[33]
Chae S, Kang KA, Chang WY, Kim MJ, Lee SJ, et al. (2009) Effect of compound K, a metabolite of ginseng saponin, combined with gamma-ray radiation in human lung cancer cells in vitro and in vivo. J Agric Food Chem 57: 5777–5782.
[34]
Jacobs JP, Jones CM, Baille JP (1970) Characteristics of a human diploid cell designated MRC-5. Nature 227: 168–170.
[35]
Jenkins DE, Oei Y, Hornig YS, Yu SF, Dusich J, et al. (2003) Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 20: 733–744.
[36]
Lee KT, Choi J, Jung WT, Nam JH, Jung HJ, et al. (2002) Structure of a new echinocystic acid bisdesmoside isolated from Codonopsis lanceolata roots and the cytotoxic activity of prosapogenins. J Agric Food Chem 50: 4190–4193.
[37]
Nalbantsoy A, Nesil T, Yilmaz-Dilsiz O, Aksu G, Khan S, et al. (2011) Evaluation of the immunomodulatory properties in mice and in vitro anti-inflammatory activity of cycloartane type saponins from Astragalus species. J Ethnopharmacol
[38]
Xu LP, Wang H, Yuan Z (2008) Triterpenoid saponins with anti-inflammatory activity from Codonopsis lanceolata. Planta Med 74: 1412–1415.
[39]
Joh EH, Lee IA, Han SJ, Chae S, Kim DH (2010) Lancemaside A ameliorates colitis by inhibiting NF-kappaB activation in TNBS-induced colitis mice. Int J Colorectal Dis 25: 545–551.
[40]
Joh EH, Kim DH (2010) Lancemaside A inhibits lipopolysaccharide-induced inflammation by targeting LPS/TLR4 complex. J Cell Biochem 111: 865–871.
[41]
Yu K, Lucas J, Zhu T, Zask A, Gaydos C, et al. (2005) PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer biology & therapy 4: 538–545.
[42]
Ihle NT, Williams R, Chow S, Chew W, Berggren MI, et al. (2004) Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Molecular cancer therapeutics 3: 763–772.
[43]
Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, et al. (2007) The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Molecular cancer therapeutics 6: 2505–2514.
[44]
Garlich JR, De P, Dey N, Su JD, Peng X, et al. (2008) A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer research 68: 206–215.
[45]
Billottet C, Banerjee L, Vanhaesebroeck B, Khwaja A (2009) Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer research 69: 1027–1036.
[46]
Maira SM, Pecchi S, Huang A, Burger M, Knapp M, et al. (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Molecular cancer therapeutics 11: 317–328.
[47]
Sato S, Fujita N, Tsuruo T (2002) Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21: 1727–1738.
[48]
Mohan AL, Friedman MD, Ormond DR, Tobias M, Murali R, et al. (2012) PI3K/mTOR Signaling Pathways in Medulloblastoma. Anticancer research 32: 3141–3146.
[49]
Fasolo A, Sessa C (2008) mTOR inhibitors in the treatment of cancer. Expert opinion on investigational drugs 17: 1717–1734.
[50]
Blake JF, Xu R, Bencsik JR, Xiao D, Kallan NC, et al. (2012) Discovery and Preclinical Pharmacology of a Selective ATP-competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors. Journal of medicinal chemistry
[51]
Wang P, Zhang L, Hao Q, Zhao G (2011) Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB. Mini reviews in medicinal chemistry 11: 1093–1107.
[52]
Meuillet EJ (2011) Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain. Curr Med Chem 18: 2727–2742.
[53]
Jo H, Lo PK, Li Y, Loison F, Green S, et al. (2011) Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination. Proc Natl Acad Sci U S A 108: 6486–6491.
[54]
Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, et al. (2005) Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. The Biochemical journal 385: 399–408.
[55]
Martelli AM, Evangelisti C, Chiarini F, McCubrey JA (2010) The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 1: 89–103.
[56]
Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV (2005) The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482–7492.
[57]
Garcia-Echeverria C, Sellers WR (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511–5526.
